PER 1.27% 7.8¢ percheron therapeutics limited

Ann: US FDA Grants RPDD to ATL1102 for the treatment of DMD, page-93

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 650 Posts.
    lightbulb Created with Sketch. 16
    happy to hold for another 2 years when everything is complete and share price is at $ to $3... we know phase 2a was a success on lower doses with increase strength and muscle mass whilist being safe and no adverse or serious side effects, also complimenting other treatments on market...

    pretty confident phase 2a done it gives an insight on 2b, happy to speculate it being another success, but who knows might be taken over and brought out by a big pharama co.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.8¢
Change
-0.001(1.27%)
Mkt cap ! $80.86M
Open High Low Value Volume
8.0¢ 8.0¢ 7.7¢ $374.4K 4.803M

Buyers (Bids)

No. Vol. Price($)
3 308385 7.8¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 818650 4
View Market Depth
Last trade - 16.10pm 04/11/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.